239 related articles for article (PubMed ID: 31884406)
1. Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: Pharmacokinetic and pharmacological study.
Feng SL; Tian Y; Huo S; Qu B; Liu RM; Xu P; Li YZ; Xie Y
Phytomedicine; 2020 Feb; 67():153141. PubMed ID: 31884406
[TBL] [Abstract][Full Text] [Related]
2. A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
Liu RM; Xu P; Chen Q; Feng SL; Xie Y
Phytomedicine; 2020 Dec; 79():153342. PubMed ID: 32992085
[TBL] [Abstract][Full Text] [Related]
3. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
[TBL] [Abstract][Full Text] [Related]
4. Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells.
Ma W; Feng S; Yao X; Yuan Z; Liu L; Xie Y
Sci Rep; 2015 Dec; 5():18789. PubMed ID: 26689156
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance.
Li J; Zheng L; Wang R; Sun D; Liang S; Wu J; Liu Y; Tian X; Li T; Yang Y; Han L
Int J Nanomedicine; 2020; 15():5839-5853. PubMed ID: 32848393
[TBL] [Abstract][Full Text] [Related]
6. Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents.
Feng S; Zhou H; Wu D; Zheng D; Qu B; Liu R; Zhang C; Li Z; Xie Y; Luo HB
Acta Pharm Sin B; 2020 Feb; 10(2):327-343. PubMed ID: 32082977
[TBL] [Abstract][Full Text] [Related]
7. Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Zhang Q; Song Y; Cheng X; Xu Z; Matthew OA; Wang J; Sun Z; Zhang X
Anticancer Res; 2019 Oct; 39(10):5461-5471. PubMed ID: 31570440
[TBL] [Abstract][Full Text] [Related]
8. An ester derivative of tenacigenin B from Marsdenia tenacissima (Roxb.) Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2.
Wu ZL; Chen Y; Qu Z; Wu GY; He XF; Huang JW; Meng QQ; Hu YH; Shen XL; Yang RY; Hu YJ
J Ethnopharmacol; 2022 Aug; 294():115353. PubMed ID: 35533911
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
10. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.
Jiang L; Wang P; Sun YJ; Wu YJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):265. PubMed ID: 31215501
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.
Wang B; Li S; Meng X; Shang H; Guan Y
Tumour Biol; 2015 Aug; 36(8):6433-43. PubMed ID: 25801244
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
[TBL] [Abstract][Full Text] [Related]
14. Physcion-8-O-β-d-glucoside interferes with the nuclear factor-κB pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells.
Li X; He Y; Wei L; Zhang J; Li X; Cui W; Zhang S
J Pharm Pharmacol; 2021 Mar; 73(4):545-552. PubMed ID: 33793827
[TBL] [Abstract][Full Text] [Related]
15. A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer.
Chen M; Song F; Liu Y; Tian J; Liu C; Li R; Zhang Q
Nanoscale; 2019 Mar; 11(9):3814-3826. PubMed ID: 30600823
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
17. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
18. Investigation on vitamin e succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy.
Hou L; Tian C; Chen D; Yuan Y; Yan Y; Huang Q; Zhang H; Zhang Z
Eur J Pharm Sci; 2019 Dec; 140():105071. PubMed ID: 31525433
[TBL] [Abstract][Full Text] [Related]
19. Effects of Kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells.
Hyuga S; Shiraishi M; Hori A; Hyuga M; Hanawa T
Biol Pharm Bull; 2012; 35(10):1729-39. PubMed ID: 23037162
[TBL] [Abstract][Full Text] [Related]
20. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]